Agilent Technologies, Inc. (A) fair value analysis
S&P 500 · Updated 2026-09-07
Agilent Technologies, Inc. is a diversified healthcare and life sciences company that develops, manufactures, and sells analytical instruments, software, and services used in laboratories and clinical settings worldwide. The company operates through multiple business segments serving pharmaceutical, chemical, food, environmental, and academic customers across North America, Europe, Asia-Pacific, and other international markets.
Forward Fair Value verdict
Fairly valuedBased on TickrTrends' weekly Forward Fair Value model, A is trading at within about 10% of estimated fair value.
A currently ranks #59 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.
- Last price
- $150.86
- Sector
- Healthcare
- 12-month range
- $114.52–$150.10
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- C
- Leverage
- Moderate
- Margin trend
- Contracting
- Revenue growth
- Declining
- RSI zone
- Neutral
- 52-week position
- The top quarter of its range
What our data shows for A
- Our model validated 17 trailing price-to-earnings windows for A, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $114.52–$150.10.
- The 14-day relative strength index sits at a neutral 58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for A
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent A news
TickrTrends' derived news-sentiment signal for A is currently leaning positive, computed from recent coverage.
- A Looks 1.1% Overvalued on GF Value™ as Insider Selling and Guru Activity Signal Caution (gurufocus.com, 2026-09-04)
TickrTrends take: A is currently assessed as fairly valued by TickrTrends within the Healthcare sector, though recent valuation analysis from GF Value suggests modest overvaluation concerns. The combination of insider selling activity and notable guru investment movements indicates that valuation-focused investors should monitor whether the current fair value assessment may shift in coming periods. Given the Healthcare sector's sensitivity to regulatory and clinical developments, watchers of A's valuation should track both insider transaction patterns and major shareholder positioning as potential early signals of fundamental reassessment. - Agilent Technologies Inc (A) Looks 2.6% Overvalued on GF Value™ (gurufocus.com, 2026-09-02)
TickrTrends take: Agilent Technologies' current TickrTrends assessment of fairly valued positioning contrasts with this external valuation signal suggesting a modest premium to intrinsic worth. A reader focused on valuation metrics should monitor whether the company's fundamentals strengthen enough to justify its current price level, or whether any pullback could offer a more compelling entry point. The Healthcare sector context matters, as investor appetite for diagnostic and life sciences tools can shift based on broader market conditions and industry tailwinds. - A Looks 3.5% Overvalued on GF Value™ as Agilent Launches Cary 635 FTIR Spectrometer (gurufocus.com, 2026-09-01)
TickrTrends take: Agilent Technologies' launch of the Cary 635 FTIR Spectrometer represents a product innovation in its analytical instruments business, which supports revenue generation in the healthcare and life sciences sectors. TickrTrends currently rates A as fairly valued, whereas the GF Value analysis suggests the stock trades at a premium to intrinsic worth. Investors focused on valuation should monitor whether this new spectrometer drives sufficient market adoption and revenue growth to justify the current stock price, or whether the valuation gap narrows as the market digests the competitive positioning of this product.
What people are saying
Follow the A conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TickrTrends' derived indicators for A in the Healthcare sector show movement this week in the sector discount ranking, which improved from number 64 to number 59. The current valuation verdict for this security remains Fairly valued.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is A stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), A is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is A's TickrTrends verdict?
A's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does A compare to other Healthcare stocks?
A ranks #59 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.
Is A overbought or oversold?
A's 14-day RSI is in neutral territory - neither overbought nor oversold.